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Human papillomavirus (HPV) infection and cervical squamous intraepithelial lesions (SILs) were studied in 379 high-risk women.
Human papillomavirus DNA was detected in 238 of 360 (66.1%) of the beta-globin-positive cervical samples, and 467 HPV isolates
belonging to 35 types were identified. Multiple (2–7 types) HPV infections were observed in 52.9% of HPV-infected women.
The most prevalent HPV types were HPV-52 (14.7%), HPV-35 (9.4%), HPV-58 (9.4%), HPV-51 (8.6%), HPV-16 (7.8%), HPV-31
(7.5%), HPV-53 (6.7%), and HPV-18 (6.4%). Human immunodeficiency virus type 1 (HIV-1) seroprevalence was 36.0%. Human
papillomavirus prevalence was significantly higher in HIV-1-infected women (87 vs 54%, prevalence ratio (PR)¼1.61, 95% confidence
interval (CI): 1.4–1.8). High-risk HPV types (71 vs 40%, PR¼1.79, 95% CI: 1.5–2.2), in particular HPV-16þ18 (22 vs 9%, PR¼2.35,
95% CI: 1.4–4.0), and multiple HPV infections (56 vs 23%, PR¼2.45, 95% CI: 1.8–3.3) were more prevalent in HIV-1-infected
women. High-grade SIL (HSIL) was identified in 3.8% of the women. Human immunodeficiency virus type 1 infection was strongly
associated with presence of HSIL (adjusted odds ratio¼17.0; 95% CI 2.2–134.1, P¼0.007) after controlling for high-risk HPV
infection and other risk factors for HSIL. Nine of 14 (63%) HSIL cases were associated with HPV-16 or HPV-18 infection, and might
have been prevented by an effective HPV-16/18 vaccine.
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Cervical cancer is the most frequent cancer of women in
developing countries, particularly in sub-Saharan Africa (Parkin
et al, 1999), and it is now well established that genital infection
with certain types of human papillomavirus (HPV) causes virtually
all cases of cervical intraepithelial neoplasia (CIN) and invasive
cervical cancer (ICC) (Walboomers et al, 1999). The HPV types
that infect the genital tract have been subdivided into low-risk
(LR) types, which are principally found in nonmalignant lesions
such as genital warts, and high-risk (HR) types, which are
associated with the development of CIN and ICC. Human
papillomavirus types 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and
89 are classified as LR types, whereas types 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 68, 73, and 82 are classified as HR types. In
addition, HPV types 26, 53, and 66 are considered as probably
carcinogenic (Mun ˜oz et al, 2003).
Human papillomavirus prophylactic vaccines are now
being developed and promising results have been obtained with
recombinant L1 capsid protein virus-like particles (VLPs).
However, the current HPV vaccines target the most prevalent
high-risk HPV (HR-HPV) types worldwide, namely HPV-16 and
HPV-18 (Koutsky et al, 2002; Ault et al, 2004; Brown et al, 2004;
Harper et al, 2004). It has been shown that crossneutralisation
induced by L1 VLPs represents less than 1% of the neutralising
activity induced by the dominant conformational epitope (Combita
et al, 2002), indicating that current HPV vaccines would be able to
confer only type-specific immunity. Therefore, effectiveness
of these vaccines on the prevention of cancer may be lower in
populations highly affected by HR-HPV types other than HPV-16
and HPV-18. Thus, it is important to document the distribution of
HPV genotypes in HPV-infected women and in women with
cervical neoplasia in African countries in order to assess the
potential effectiveness of a bivalent HPV-16/18 vaccine.
There have been few detailed studies of HPV genotypes and
their association with intraepithelial lesions or ICC in sub-Saharan
Africa. Available data suggest, however, a higher prevalence and
wider spectrum of oncogenic HPV types compared to studies
conducted elsewhere (Castellsague et al, 2001; De Vuyst et al,
2003; Mayaud et al, 2003; Clifford et al, 2005; Wall et al, 2005).
Furthermore, the high background prevalence of human immuno-
deficiency virus type 1 (HIV-1) observed in many African settings
adds complexity to our understanding of the epidemiology of HPV
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sand cervical neoplasia. Studies conducted in industrialised
countries have shown that HIV-1 alters the natural history of
HPV infection by upregulating HPV persistence and recurrences,
thereby facilitating progression to high-grade lesions and
cancer (Sun et al, 1997; Ahdieh et al, 2001; Strickler et al, 2005).
Consequently, cervical cancer has been included in the list of
AIDS-defining opportunistic conditions by the Centres for
Disesase Control and Prevention (Centers for Disease Control
and Prevention, 1993). However, the relationships between HIV-1,
HPV and squamous intraepithelial lesions (SIL) in sub-Saharan
Africa are unclear. Some studies have found no association
between HIV-1 and HPV (Mayaud et al, 2001), others found an
association between HIV-1 and HPV, but no association between
HIV-1 and SIL (De Vuyst et al, 2003), while others found a strong
association between HIV-1, HR-HPV, high-grade SIL (HSIL), and
cervical cancer (La Ruche et al, 1998; Chirenje et al, 2002; Hawes
et al, 2003). Surprisingly, the relentless progression of the AIDS
epidemic on the African continent has not been paralleled by
increases in cervical cancer rates, in contrast with rates of other
AIDS-linked cancers, such as Kaposi’s sarcoma or non-Hodgkin’s
lymphomas (Parkin et al, 1999). This may be due, in part, to
a much-reduced life expectancy among HIV-1-infected women in
Africa contrasting with a long duration for ICC development.
Further understanding of this relationship is essential in order to
assess the possible response to a newly introduced HPV-16/18
vaccine in such populations.
In Burkina Faso, a country in West Africa with an estimated
HIV-1 prevalence among the general adult population of 4.2%
(http://www.unaids.org), virtually nothing is known of the
epidemiology of HPV and HPV-related malignancies, and the
impact of HIV on these conditions. The aim of the present study
was to determine the prevalence of HPV infection, the distribution
of HPV genotypes, the frequency of SIL, and their relationships
with HIV-1, in a group of high-risk women in Bobo Dioulasso, the
second largest city of Burkina Faso.
MATERIALS AND METHODS
Study population and sample collection
We performed a cross-sectional survey nested within the Yerelon
cohort study, a research programme that aims to design,
implement, and evaluate interventions reducing the risk of
HIV-1 and other sexually transmitted infections (STI) among
female sex workers (FSWs). The cohort inclusion process has
been described elsewhere (Nagot et al, 2002). In brief, FSWs were
informally approached at their place of work (streets, bars, or
home) through an existing network of trained peer educators, and
women were referred to the Centre Municipal d’Hygiene, a public
health facility in Bobo Dioulasso. After extensive information and
a reflection period of at least 2 weeks, women consenting to
participate were invited to answer a standardised questionnaire
eliciting information on sociodemographic factors, sexual beha-
viour, past and current sexual health. Women were examined with
a speculum during which genital samples were collected for the
diagnosis of vaginal and cervical infections. Blood samples were
drawn for HIV, syphilis and Herpes simplex virus type 2 (HSV-2)
serologies. Participants were followed up every 4 months with
serological re-testing as appropriate.
Between December 2003 and March 2004, consecutive women
taking part in the cohort study were requested permission for an
additional cervical swab for liquid-based cytology and HPV-DNA
detection using a Cervex brush (Cytyc, Montrouge, France). The
brush was stirred into a vial of PreservCyt transport solution
(Cytyc) and kept at room temperature until shipment to the
Pathology Laboratory at the University Hospital, Montpellier,
France. The Yerelon Cohort Research Programme has been
approved by the Ethical Committee of the Centre Muraz, Bobo
Dioulasso, the National Ethical Committee of the Ministry of
Health, Burkina Faso, and the Ethics Committee of the London
School of Hygiene and Tropical Medicine.
Cervical cytology
Thin-layer cytological smears were prepared from the Cytic cell
suspension vial by controlled membrane transfer technology using
the ThinPrep 2000 processor (Cytyc). After Papanicolaou (Pap)
staining, slides were independently examined by two senior
pathologists who were blinded to all other study results. The
2001 Bethesda classification (Smith, 2002) was used for slide
interpretation.
HPV detection and typing
DNA was extracted from the residual cell suspension as described
previously (Gravitt et al, 2000). Samples were tested for the
presence of amplifiable DNA and absence of PCR inhibitors by
performing beta-globin PCR (Saiki et al, 1988). Two single-step
PCRs using consensus primer pairs were performed on the beta-
globin-positive samples using first the primer pair MY09/MY11,
which allows amplification of a 450bp fragment in the HPV L1
gene (Manos et al, 1989); negative samples were tested using the
primer pair GP5þ/GP6þ, which allows amplification of a 140bp
fragment in L1 (de Roda Husman et al, 1995) and the samples
found negative by both MY09/MY11- and GP5þ/GP6þ-mediated
single-step PCRs were tested by nested PCR using the primers
MY09/MY11 in the first round and the primers GP5þ/GP6þ in
the second round. The MY09 primer mixture contained the HPV-
51-specific HMB01 oligonucleotide as described previously (Gravitt
et al, 2000). The amplification mixtures contained 50pmol of each
primer in the presence of 1 PCR buffer, 6mM (MY09/MY11
primers), or 4mM (GP5þ/GP6þ primers) MgCl2, 200mmol
(each) dNTPs, 1.5U of AmpliTaq gold DNA polymerase (Applied
Biosystems, Courtaboeuf, France), and 5ml of DNA extract in a
volume of 50ml. The PCR conditions were 951C for 9min, followed
by 40 cycles of 951C for 1min, 551C (MY09/MY11 primers) or 381C
(GP5þ/GP6þ primers) for 1min and 721C for 1min, and a final
extension at 721C for 5min. For the nested PCR, 2ml of the first-
round product were used in the second-round PCR.
HPV typing of the HPV DNA-positive samples was performed
using the INNO-LiPA HPV Genotyping v2 test (Innogenetics,
Ghent, Belgium). This test is based on the amplification of a part
of the L1 region of the HPV genome using the broad-spectrum
SPF10-biotinylated primers. Biotinylated amplicons are subse-
quently hybridised with HPV type-specific oligonucleotide probes,
which are immobilised as parallel lines on membrane strips.
After hybridisation and stringent washing, streptavidin-conjugated
alkaline phosphatase is added and bound to any biotinylated
hybrid formed. Incubation with BCIP/NBT chromogen yields a
purple precipitate and the results can be visually interpreted
(Kleter et al, 1999). This test allows detection of 24 HPV types,
namely HR-HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
and 68, LR-HPV types 6, 11, 40, 42, 43, 44, 54, 70, and 74, and the
probably oncogenic HPV types 53 and 66.
In addition, HPV typing was performed by sequencing and
phylogenetic analyse on HPV DNA-positive samples that could
not be typed using the INNO-LiPA Genotyping v2 test. The
PCR products obtained using the GP5þ/GP6þ primers were
directly sequenced with the BigDye Terminator cycle sequencing
kit v3.1 (Applied Biosystems) on the ABI PRISM 3100
genetic analyser (Applied Biosystems); GP5þ and GP6þ primers
served as forward and reverse primers, respectively. The
nucleotide sequences were aligned and compared with those
of known HPV types available through the GenBank database
(http://www.ncbi.nlm.nih.gov/) by use of the CLUSTAL W multiple
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tructed by the neighbour-joining method and reliability of the
branching orders was assessed by the bootstrap approach
with CLUSTAL W. A nucleotide sequence was assigned to a
HPV type if it displayed greater than 90% homology with this type
(de Villiers et al, 2004).
Other reproductive tract infection (RTI) or STI
Vaginal smears were examined microscopically for the presence
of Trichomonas vaginalis, Candida spp, and bacterial vaginosis
(using the Nugent’s score on a Gram-stained smear; Nugent et al,
1991). One cervical swab was cultured onto modified Thayer–
Martin media plates using standard procedures to detect the
presence of Neisseria gonorrhoeae. Molecular diagnosis of
Chlamydia trachomatis was not available at the time of the survey,
but this infection had been shown to be rare by PCR (o2%) in this
population (Nagot et al, 2004). Venous blood samples were tested
for: HIV-1 and -2 serologies, using a validated national strategy
based on two independent ELISA tests (Meda et al, 1999); syphilis
serology, by rapid plasma reagin test (RPR, Human GmbH,
Wiesbaden, Germany) with reactive sera confirmed by Treponema
pallidum haemagglutination assay (TPHA, Newmarket Labora-
tories Ltd, Kentford, UK); and HSV-2 serology, using a specific
gG2-ELISA test (Kalon HSV-2, Kalon Biologicals, Aldershot, UK)
proved to have a good sensitivity and specificity on African sera
(Van Dyck et al, 2004). CD4 lymphocyte counts were measured
from blood samples using a standard flow cytometric method.
Data analysis
Data were analysed using STATA 8.1 (StataCorp, College Station,
TX, USA). Associations between HIV and HPV were assessed
with prevalence ratios (PR) and their 95% confidence intervals
(95% CI). Associations between HSIL and exposures were
assessed with odds ratios (OR) and 95% CI, as HSIL was a rare
event, and statistically tested by Fisher’s exact test and w
2 for
trend where appropriate. Adjusted ORs (AOR) and corresponding
95% CI were calculated by multiple logistic regression for
factors significantly associated with HSIL in univariate analysis
(i.e., with P-values o0.1, or crude OR X2o ro0.5), or for
known risk factors for HSIL reported in the literature (e.g.,
young age at first sex, smoking, hormonal contraception,
presence of other STIs, or low CD4 cell count). Associations of
prevalence of HPV types with cervical lesions categories were
tested by w
2 for trend.
RESULTS
Study population characteristics, HIV-1, and RTI/STI
prevalence
A total of 379 women were seen during the study period and
all agreed to participate. Their median age was 28.0 years (range
16–54 years) and the mean age at first sexual intercourse was
16.7 years. Participants had been involved in commercial sex
for a median of 3.2 years, with a median number of 3.3 weekly
sexual partners. Condoms were reportedly used in all sexual
encounters with first-time clients by 77.1% of women, but were
seldom used with their regular partner. Only 12% of participants
used hormonal contraception and 7% were current smokers.
Prevalence of bacterial vaginosis, C. albicans, and T. vaginalis
were 42.4, 6.8, and 9.6% respectively, and no diagnosis of N.
gonorrhoeae was made. Only two cases of serological syphilis
(RPR- and TPHA-positive sera) were detected. Human immuno-
deficiency virus type 1 and HSV-2 seroprevalence were 36.6 and
69.8%, respectively.
HPV detection and typing
Cervical samples were obtained from all 379 women, and 360
(95.0%) were positive for beta-globin DNA. The prevalence of
cervical HPV was 66.1% (238 of 360): 114 samples were positive
with the MY09/MY11 primer pair, 50 were positive with the
GP5þ/GP6þ primer pair, and 74 were positive by nested PCR.
Human papillomavirus types could be identified by LiPA in 211
samples and by sequencing in the remaining 27 samples. A total
of 467 HPV infections belonging to 35 types were identified
(Figure 1). The most prevalent HPV types were HPV-52 (14.7%),
HPV-35 (9.4%), HPV-58 (9.4%), HPV-51 (8.6%), HPV-16
(7.8%), HPV-31 (7.5%), HPV-53 (6.7%), and HPV-18 (6.4%).
Multiple HPV infections (2–7 types) were identified in 126 of
360 (35.0%) women and accounted for 52.9% (126 of 238) of
HPV-infected women.
Cervical cytology
Interpretable cervical smears were obtained from 366 (97%)
women. Squamous intraepithelial lesion were detected in 88
(24.0%) women, with 74 (20.2%) being classified as LSIL and 14
(3.8%) as HSIL. Thirteen (3.5%) samples were classified as atypical
squamous cells of undetermined significance (ASCUS).
Relationships between HIV-1, HPV infection, and
cervical SIL
A total of 350 women had a complete set of data available,
including an interpretable Pap smear, a positive beta-globin DNA
PCR and known behavioural and demographic characteristics.
Among these women, 126 (36.0%) were infected with HIV-1 and 30
(23.8%) of them had a CD4 cell count o200cellsml
 1. One woman,
infected with HIV-2 alone (and infected with HPV-70) was
excluded from further analyses. Subsequent analyses are based
on the 349 remaining women.
As shown in Table 1, the prevalence of HPV infection was
significantly higher in HIV-1-infected women, mainly owing to a
higher prevalence of HR-HPV, including HPV types 16 and 18. The
prevalence of multiple HPV infection was also increased in
HIV-1-infected women. Age-related HPV prevalence according to
HIV-1 serostatus is shown in Figure 2. Among HIV-1-seronegative
women, HR-HPV infection varied significantly, being more
frequent in the younger and older age groups (P¼0.03). In
contrast, there was no statistically significant association of HPV
with age among HIV-1-seropositive women (P¼0.9).
Despite the participants’ young age, a high prevalence (24.9%)
of cervical cytological abnormalities was observed (Table 2). As
expected, SIL was more prevalent among the HPV-positive women
(Po0.001), and among women with multiple HPV infections
compared to those infected with a single HPV type (54 of 123
(43.9%) vs 24 of 109 (22.0%), Po0.001). Among HPV-infected
women, prevalence of SIL was significantly higher among those
co-infected with HIV-1 (Po0.001). HSIL was observed exclusively
among HPV-infected women, and all but one HSIL cases were
observed among HIV-1-infected women (Po0.001) (Table 2). Only
HIV-1 infection and HR-HPV types were statistically significantly
associated with HSIL in univariate analysis (Table 3), while low
CD4 cell count (o200cellsml
 1) had an association of borderline
significance. None of the classical cofactors of HSIL (e.g., age
at fist sex, smoking, presence of other STIs) reported in the
literature were associated with HSIL in this study, in part because
of the small number of HSIL cases and/or the low prevalence
of some of these variables. In multivariate analysis, only HIV-1
infection remained strongly associated with the presence of HSIL
(AOR¼17.0, 95% CI: 2.2–134.1, P¼0.007), while there was
suggestion for a nonstatistically significant association between
HR-HPV and HSIL (AOR¼7.0, 95% CI 0.9–55.6, P¼0.07).
HPV genotypes, SIL, and HIV-1 in Burkina Faso
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we have examined the prevalence of HPV-16- and HPV-18-related
infections according to HIV-1 serostatus and cervical lesions
categories (Table 4). Human papillomavirus-16 was the most
prevalent (42.9%) genotype among the 14 women with HSIL, while
HPV types 16 or 18 were found in nine (64.3%) of these women.
All but one woman with HSIL – who was infected with HPV types
54 and 66 – were infected with HPV types belonging to HPV-16- or
HPV-18-related phylogenetic groups.
DISCUSSION
This is the first report of an epidemiological study of cervical HPV
and SIL in Burkina-Faso. We did not conduct a general
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Figure 1 Distribution of HPV types identified among 349 high-risk women in Bobo-Dioulasso, Burkina Faso.
Table 1 Infection with high-risk or low-risk HPV types according to HIV-1 status, among 349 high-risk women in Bobo Dioulasso, Burkina Faso
HIV-1 status
Positive (n¼126) Negative (n¼223)
HPV types No. (%) No. (%) Prevalence ratio (95% CI)
HPV-positive 110 (87) 121 (54) 1.61 (1.4–1.8)
At least one high-risk HPV type 89 (71) 89 (40) 1.79 (1.5–2.2)
Infection with HPV-16 and/or -18 28 (22) 21 (9) 2.35 (1.4–4.0)
Low-risk HPV type only 21 (17) 32 (14) 1.12 (0.8–1.6)
Multiple HPV infections 71 (56) 51 (23) 2.45 (1.8–3.3)
CI¼confidence interval; HIV¼human immunodeficiency virus; HPV¼human papillomavirus.
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spopulation-based study but decided to target a population of
highly sexually exposed women. Such women are likely to
concentrate the majority of HPV types circulating in the general
population of the region, thereby providing some of the
information required to assess the usefulness of an HPV vaccine.
Moreover, our choice of study population allowed, with an
economical sample size, exploration of the relationships between
HPV subtypes, presence of SIL, and the role played by HIV in
promoting persistence of HPV and progression to HSIL. This is
critical information since, ultimately, an HPV vaccine’s effective-
ness will depend upon the proportion of HSIL and ICC cases
attributable to the subtypes included in the vaccine, and possibly
the background HIV prevalence in the population, which might act
as a catalyst in the upregulation of certain HPV types. Moreover,
in some sub-Saharan settings, it is conceivable that HSIL and
ICC may disproportionately be found among young HIV-positive
women. Thus, although the epidemiological picture found in our
study population might not be indicative of infection levels in the
general population of Burkina Faso, the diversity of HPV types
found and their association with cervical lesions would constitute
valid and important data to inform HPV vaccine strategies in the
country. Finally, our study represents one of the most detailed and
exhaustive molecular studies of HPV in sub-Saharan Africa, which
is an important prerequisite in describing HPV epidemiology.
Indeed, we detected HPV DNA in cervical samples using the two
most commonly used consensus PCR primer sets for genital
HPV, namely MY09/MY11 and GP5þ/GP6þ (Qu et al, 1997), and
samples found negative by both PCR reactions were tested by
nested PCR. Positive HPV samples were typed by LiPA and by
sequencing when LiPA was inconclusive, leaving no sample
unidentified.
While the epidemiology of genital HPV types has been relatively
better studied in Southern and Eastern African countries such
as Kenya (Temmerman et al, 1999; De Vuyst et al, 2003), Malawi
(Miotti et al, 1996), Mozambique (Castellsague et al, 2001),
Tanzania (Mayaud et al, 2003), Uganda (Serwadda et al, 1999), and
Zimbabwe (Gravitt et al, 2002; Baay et al, 2004), data from Western
Africa have been scarce. The prevalence of HPV infection and
associated cervical lesions have been studied in Ivory Coast (La
Ruche et al, 1998) and Mali (Bayo et al, 2002), but detailed HPV
types were only reported from Senegal (Xi et al, 2003), Nigeria
(Thomas et al, 2004), and The Gambia (Wall et al, 2005).
Prevalence rates of HPV infection ranging from 13 to 40% have
been reported from low-risk or general populations of sub-Saharan
African countries (Miotti et al, 1996; Temmerman et al, 1999;
Castellsague et al, 2001; De Vuyst et al, 2003; Mayaud et al, 2003;
Xi et al, 2003; Baay et al, 2004; Thomas et al, 2004; Wall et al,
2005). The 66% prevalence found in the present study, which is
still much higher than the 40% prevalence found in similar high-
risk populations in Africa (Kreiss et al, 1992; Langley et al, 1996;
Piper et al, 1999), might reflect the high sexual exposure of our
study population and, as mentioned earlier, may be attributed in
part to the exhaustive nature of our HPV detection strategy.
Indeed, the use of a primer pair alone to detect HPV by PCR may
be responsible for the underestimation of infections with certain
HPV types. For example, HPV types 26, 35, 42, 45, 52, 54, 55, 59,
66, 68, 73, and 83 may be missed by using only the MY09/MY11
primer pair (Qu et al, 1997; Gravitt et al, 2000). Human
papillomavirus-52, HPV-35, and HPV-58 were the most prevalent
types in the present study. A high prevalence of these HPV
types has been also observed in other African studies (Gravitt
et al, 2000; Castellsague et al, 2001; De Vuyst et al, 2003;
Mayaud et al, 2003; Xi et al, 2003; Baay et al, 2004; Thomas et al,
2004; Wall et al, 2005).
The higher HR-HPV prevalence observed in the younger (o25
years) and older (440 years) HIV-1-seronegative women com-
pared to the middle age groups is consistent with high rates of
HPV acquisition following entry into sexually active life, and
high rates of recurrence or persistence associated with older
ages, as described elsewhere (Castle et al, 2005). Although HR-
HPV infection rates were much higher, there was no statistically
significant association with age among the HIV-1-positive women,
possibly reflecting the process of upregulation and persistence of
HPV elicited by HIV-1, as suggested by others (Palefsky et al, 1999;
Ahdieh et al, 2001; Moscicki et al, 2004b), independent of age.
A high prevalence of HIV-1 infection was observed in our study
population, and HIV-1 infection was associated with an increased
rate of HPV infection, mainly restricted to HR-HPV types.
This finding may result from the high level of sexual exposure to
both viruses as well as, as mentioned above, from persistence or
recurrence of oncogenic HPV following HIV-1 induced immuno-
suppression. We also found that HIV-1 infection was indepen-
dently associated with an increase in SIL among HPV-positive
women and that HIV-1 represented an important risk factor
for the presence of HSIL. These findings are in agreement with
other African series (La Ruche et al, 1998; Chirenje et al,
2002; Hawes et al, 2003) and with many studies in industrialised
countries (Sun et al, 1997; Ahdieh et al, 2001; Moscicki et al, 2004b;
Strickler et al, 2005).
More than half of the HPV-infected FSWs presented multiple
HPV infection, which was associated with higher HIV-1 and SIL
prevalence. Previous studies have reported a high prevalence of
multiple HPV infections among HIV-infected women (Palefsky
et al, 1999; Gravitt et al, 2002) which is associated with an
increased risk of intraepithelial neoplasia and of cancer (Moscicki
et al, 2004a; Herrero et al, 2005).
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Figure 2 Distribution of HPV infection according to age and HIV-1
status among 349 women in Bobo Dioulasso, Burkina Faso. Numbers of
women in groups are indicated at the top of bars. The hatched part of the
bar represents the proportion of women infected with at least one high-risk
HPV type, whereas the unicoloured part represents the proportion of
women infected with low-risk HPV types only.
Table 2 Prevalence of SILs according to HPV and HIV-1 status among
349 high-risk women in Bobo Dioulasso, Burkina Faso
No. (%) of cervical lesions
a
HPV and HIV-1 status LSIL HSIL All SIL
HPV  HIV-1  (n¼102) 7 (6.9) 0 (0.0) 7 (6.9)
HPV  HIV-1+ (n¼16) 2 (12.5) 0 (0.0) 2 (12.5)
HPV+ HIV-1  (n¼121) 18 (14.9) 1 (0.8) 19 (15.7)
HPV+ HIV-1+ (n¼110) 46 (41.8) 13 (11.8) 59 (53.6)
All (N¼349) 73 (20.9) 14 (4.0) 87 (24.9)
HIV¼human immunodeficiency virus; HPV¼human papillomavirus; HSIL¼high-
grade SIL; LSIL¼low-grade SIL; SIL¼squamous intraepithelial lesions.
aAtypical
squamous cells of undetermined significance (ASCUS) are not included.
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sTable 3 Univariate analysis: associations between HSIL and sociodemographic, behavioural, and biological factors among 349 high-risk women in Bobo
Dioulasso, Burkina Faso
Characteristics
a HSIL/total (%) (14/349) Crude OR (95% CI)
P-value for Fisher’s exact test
or for test for trend
b
Sociodemographic factors
Age (years) (n¼349)
15–24 0/144 (0) NC 0.001
25–34 9/137 (7) 1 0.09
35–39 4/34 (11) 1.67 (0.5–5.8) 0.05
440 1/29 (3) 0.49 (0.06–4.1) 1
Parity (n¼300)
Nulliparous 1/52 (2) 1
Parity 1–3 7/177 (4) 0.48 (0.05–4.0)
Parity 4+ 5/66 (7) 0.26 (0.03–2.3) 0.4*
Behavioural factors
Age at first sex (years) (n¼323)
418 2/13 (15) 1
15–18 9/207 (4) 0.25 (0.05–1.3)
p15 2/103 (2) 0.11 (0.01–0.9) 0.06*
No. years in sex work (n¼311)
o2 3/159 (2) 1
X2 9/152 (6) 3.27 (0.9–12.4) 0.08
Smoking (n¼348)
No 13/322 (4) 1
Yes 1/26 (4) 0.95 (0.1–7.6) 1
Biological factors
Hormonal contraception (n¼258)
No 8/211 (4) 1
Yes 3/47 (6) 1.73 (0.4–6.8) 0.4
HR-HPV types (n¼349)
Not present 1/171 (0.6) 1
Present 13/178 (7.3) 13.4 (1.7–107.1) 0.002
T. vaginalis (n¼299)
Not present 10/272 (4) 1
Present 0/29 (0) NC 0.6
HSV-2 serology (n¼347)
Negative 3/106 (3) 1
Positive 11/241 (4) 1.4 (0.4–6.0) 0.6
HIV-1 serology (n¼349)
Negative 1/223 (0.4) 1
Positive 13/126 (10) 25.5 (3.1–211.1) o0.001
CD4 count (in HIV+) (n¼113)
X200cellsml
 1 5/86 (6) 1
o200cellsml
 1 5/27(19) 3.68 (0.9–14.3) 0.06
CI¼confidence interval; HIV¼human immunodeficiency virus; HPV¼human papillomavirus; HR-HPV¼high-risk HPV genotypes; HSIL¼high squamous intraepithelial lesions;
NC¼odds ratio (OR) not calculated as cell value¼0.
aDifferent denominators for some characteristics, depending on questionnaire structure, and some missing data.
bTest for
trend.
Table 4 Infection with HPV-16 and -18 related types according to HIV-1 status and Pap smear result among 349 women in Bobo Dioulasso, Burkina Faso
HIV-1 status
Positive (n¼126) Negative (n¼223)
No. (%) with cytological result No. (%) with cytological result
HPV status
HSIL
(n¼13)
LSIL
(n¼48)
ASCUS
(n¼2)
Normal
(n¼63) P-value
a
HSIL
(n¼1)
LSIL
(n¼25)
ASCUS
(n¼10)
Normal
(n¼187) P-value
a
HPV-16 only 5 (38) 6 (13) 1 (50) 1 (2) o0.001 1 (100) 2 (8) 0 (0) 11 (6) 0.001
HPV-18 only 3 (23) 7 (15) 0 (0) 6 (10) 0.5 0 (0) 1 (4) 1 (10) 5 (3) 0.6
HPV-16 or -18 8 (62) 12 (25) 1 (50) 7 (11) 0.001 1 (100) 3 (12) 1 (10) 17 (9) 0.03
HPV-16 group
b 10 (77) 33 (69) 2 (100) 25 (40) 0.003 1 (100) 12 (48) 5 (50) 47 (25) 0.02
HPV-18 group
c 5 (38) 17 (35) 1 (50) 19 (30) 0.8 0 (0) 5 (20) 3 (30) 23 (12) 0.3
HPV-16 group or
HPV-18 group
12 (92) 39 (81) 2 (100) 33 (52) 0.001 1 (100) 15 (60) 6 (60) 62 (33) 0.01
ASCUS¼atypical squamous cells of undetermined significance; HIV¼human immunodeficiency virus; HPV¼human papillomavirus; HR¼high-risk types; HSIL¼high-grade
squamous intraepithelial lesions; LR¼low-risk types; LSIL¼low-grade squamous intraepithelial lesions.
aw
2 for trend over cervical abnormalities categories.
bHPV-16 phylogenetic
group includes the following HPV sub-types: 16, 31, 33, 35, 52, 58, and 67.
cHPV-18 phylogenetic group includes the following HPV sub-types: 18, 39, 45, 59, 68, and 70.
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Chabaud et al, 1996; La Ruche et al, 1998; Bayo et al, 2002; Kay
et al, 2003), HPV-16 and -18 were less common than other HR-
HPV types overall, but they were involved in 64% of HSIL lesions,
while 93% of women with HSIL had viruses related to the HPV-16
or HPV-18 phylogenetic groups. Therefore, administration of a
bivalent HPV-16/18 vaccine in this population before they get
exposed might have the potential to prevent the majority of high-
grade lesions in this population, but this would need to be
determined in prospective studies. It is not known, however,
whether successful control of HPV-16 or -18 might not lead to
replacement by other oncogenic HPV types, which are highly
prevalent in our population as in many parts of sub-Saharan Africa
(Mun ˜oz et al, 2004).
In conclusion, our study confirms the high diversity of HPV
genotypes, the burden of HPV-related cervical lesions, the role of
HIV-1 as a cofactor of HPV persistent infection, multiple-type
infection, and SIL in highly sexually exposed young African
women. The potentially preventable nature of prevalent HPV types
constitutes a compelling argument to propose HPV-16/18 vaccina-
tion to such highly vulnerable populations. However, the safety,
immunogenicity and impact of these vaccines in populations with
high background HIV-1 prevalence, remain to be determined.
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